California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC

Key Points

• California State Teachers Retirement System increased its Celcuity stake by 91.2%, purchasing 12,201 additional shares to own 25,580 shares valued at approximately $2.92 million. Institutional investors and hedge funds collectively own 63.33% of the company.
• Analysts remain broadly positive, with 10 Buy ratings and one Sell rating producing a consensus “Moderate Buy” recommendation and an average price target of $155.18.
• Celcuity shares opened at $92.79, well below their 52-week high of $151.02. The clinical-stage biotechnology company recently reported a quarterly loss of $0.97 per share, beating analyst expectations of a $1.07 loss.

California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 91.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,580 shares of the company's stock after buying an additional 12,201 shares during the quarter. California State Teachers Retirement System owned about 0.05% of Celcuity worth $2,920,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC lifted its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after buying an additional 319 shares in the last quarter. US Bancorp DE increased its position in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its position in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Parallel Advisors LLC bought a new position in shares of Celcuity in the first quarter worth about $38,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity in the fourth quarter worth about $42,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CELC shares. Guggenheim reiterated a "buy" rating on shares of Celcuity in a research report on Wednesday, June 3rd. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a research report on Thursday, May 28th. Weiss Ratings upgraded shares of Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 4th. Leerink Partners set a $155.00 price objective on Celcuity in a report on Tuesday, June 2nd. Finally, Craig Hallum reiterated a "buy" rating and issued a $178.00 price objective on shares of Celcuity in a research report on Wednesday, July 15th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $155.18.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $92.79 on Monday. The stock has a market capitalization of $4.53 billion, a P/E ratio of -23.79 and a beta of 0.21. Celcuity, Inc. has a 1-year low of $44.16 and a 1-year high of $151.02. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The business has a 50-day moving average price of $94.57 and a two-hundred day moving average price of $109.10.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.10. Equities analysts predict that Celcuity, Inc. will post -3.76 earnings per share for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source